Articles

Find an Article

Filter articles

Showing 1 to 10 of 707 results

Sovereign immunity: a venue-dependent protection

US06-04-2021Simon Roberts, Nitya Anand and Eric Wang

A recent University of Texas dispute perfectly illustrates the differing role sovereign immunity takes in proceedings at the Patent Trial and Appeal Board and district court, say Simon Roberts, Nitya Anand and Eric Wang of Hogan Lovells.

EPO’s new examination guidelines: what you need to know

EU06-04-2021Clare Roskell and Samantha Moodie

The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.

The uncertain future of antibody claims

US01-04-2021Benjamin Pelletier

Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.

Got a patent, now where to validate?

EU22-03-2021Sarah Kostiuk-Smith

For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.

Patent filing strategies for pharma startups

International16-03-2021Jian Siang Poh and Angus Fairbairn

Patents are a key asset for pharmaceutical startups, but where are they choosing to file? Jian Siang Poh and Angus Fairbairn of Marks & Clerk report.

Texas Uni’s sovereign immunity fail went as expected

US04-03-2021Gary Frischling

The result of the sovereign immunity bid mirrored previous cases but we did learn something about the opinions of Justices on the issue, says Gary Frischling of Milbank.

Second medical use: a regulatory perspective

UK08-02-2021Jackie Mulryne

Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.

The importance of Minerva Surgical v Hologic

US02-02-2021Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks

A decision by the Supreme Court over the assignor estoppel doctrine could have far-reaching implications for patent law, argue Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks of Snell & Wilmer.

What 2020 means for the life sciences

International, UK15-12-2020Sally Shorthose and Rumana Khanom

Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.

Pricing, patents and the PMPRB in Canada

Canada14-12-2020Micheline Gravelle and Iris Cheung

Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.

Showing 1 to 10 of 707 results

LSIPR